<DOC>
	<DOCNO>NCT01464164</DOCNO>
	<brief_summary>The purpose study determine safety dose drug Sotatercept , subcutaneous injection , stimulate production red blood cell production . To give every 28 day four dos .</brief_summary>
	<brief_title>Safety Efficacy Study Sotatercept Adults With Transfusion Dependent Diamond Blackfan Anemia</brief_title>
	<detailed_description>This study adult patient Diamond Blackfan Anemia currently transfuse every 3- 4 week . The drug give subcutaneous injection within one three dose level . The first dose level ( 0.1 mg/kg ) include 3 subject receive dose drug monthly total 4 dos , long dose- limiting toxicity ( DLTs ) . A Dose limit toxicity define inability deliver schedule dos toxicity &gt; /= Grade 3 , accord NCI Toxicity Grading Scale . Once 3 subject receive tolerate low dose level , next level open ( 0.3 mg/kg ) 3 new subject . Subjects monitor closely response side effect . If 2 subject dose limit toxicity first dose level , dose level -1 ( 0.05 mg/kg ) open , enrol 3 subject . If 2 subject dose level -1 , dose limit toxicity , study discontinue . If additional dose limit toxicity , dose level -1 maximum tolerate dose . There total 3 dose level , include dose level -1 . Once maximum tolerate dose reach , total 10 additional subject enrol . Protocol Amendment : The protocol amend include additional enrollment 20 subject two additional dose level Sotatercept ( 0.075 mg/kg 0.100 mg/kg ) give without prednisone boost . Efficacy measure response . A complete response determine subject long require transfusion , study drug . A partial response measure reduction 50 % need transfusion . Treatment modification make base evidence side effect . Dose- escalation perform side effect report efficacy evidence . Treatment stop hemoglobin &gt; 12 gm/dl and/ &gt; /+ grade 3 adverse event relate sotatercept . Study assessment include : - Physical exam ( height , weight , vital sign blood pressure ) screening , day 1 cycle monthly 3 month follow period well study discontinuation . - Additional blood pressure monitor day 1 cycle weekly cycle 4 , monthly follow period study discontinuation . - Karnofsky performance status screening , day 1 cycle 2 day 1 monthly follow period 3 month study discontinuation . - CBC reticulocyte count ANC collect day 1 cycle weekly cycle 4 , monthly follow period study discontinuation . - Blood chemistry , liver kidney function assess screening , day 1 15 cycle 1 , day 1 cycle 2 , 3 , 4 month 1 follow study discontinuation . - Blood iron status ( serum iron , transferrin % , ferritin ) collect screening period , month 1 follow-up period well study discontinuation . - Folate B12 level assess screening period day 1 cycle 3 study discontinuation . - Urinalysis ( creatinine , protein ) , screen , day 15 cycle 1 , day 1 cycle 2 , 3 , 4 monthly follow-up study discontinuation . - Serum erythropoietin screening , day 15 cycle 1 , day 1 cycle 3 , monthly follow-up study discontinuation . - FSH &amp; LH ( everyone ) , DHEA &amp; testosterone ( male ) , estrogen &amp; estradiol ( female ) screening , day 1 cycle 2 , 3 , 4 , monthly follow- period study discontinuation . - EKG &amp; ECHO screening , day 1 cycle 3 first month follow-up period study discontinuation - Dexa Scan screening , day 1 monthly follow-up period study discontinuation - Transfusion assessment screening , day 1 , 8 , 15 22 cycle 1 , day 1 15 cycle 2 , 3 , 4 , monthly follow-up period study discontinuation . - Response assessment day 8 , 15 , 22 cycle 1 , day 1 15 cycles2 , 3 , 4 , monthly 3 month follow-up period study discontinuation - Adverse event , concomitant therapy assess day 1 , 8 , 15 , 22 cycle 1 , day 1 15 cycle 2 , 3 , 4 , monthly follow-up period study discontinuation - Drug administration day 1 cycle 1 , 2 , 3 , 4 .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>&gt; /= 18 year age DBA diagnose RBC transfusion dependence ( define &gt; /= 10 cc/kg RBC per 28 day average ) Karnofsky performance scale &gt; /= 70 Females childbearing potential use birth control study participation 112 day follow last dose sotatercept Males must agree use latex condom sexual contact female childbearing potential participating study 112 day follow last dose sotatercept Agreement adhere study visit schedule , understand comply protocol requirement Understand sign write informed consent Creatinine clearance &lt; 30 ml/min SGOT &gt; 3x upper limit normal , SGPT &gt; 3x upper limit normal , bilirubin &gt; 3x upper limit normal Heart disease ( NY Heart Association classification &gt; /= 3 History hypertension Subjects currently responsive corticosteroid treatment Diamond Blackfan anemia Treatment another investigational drug device &lt; 56 day prestudy entry Pregnant lactating female Cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diamond Blackfan anemia</keyword>
	<keyword>DBA</keyword>
	<keyword>Blackfan Diamond anemia</keyword>
	<keyword>Congenital pure red cell aplasia</keyword>
	<keyword>Aase-Smith II Syndrome</keyword>
	<keyword>Aase Syndrome</keyword>
	<keyword>Anemia , Congenital Pure Red Cell</keyword>
	<keyword>Aplasia , Congenital Pure Red Cell</keyword>
	<keyword>BDA</keyword>
	<keyword>Congenital Hypoplastic Anemia</keyword>
	<keyword>Erythrogenesis Imperfecta</keyword>
	<keyword>Hypoplastic Congenital Anemia</keyword>
	<keyword>Inherited Erythroblastopenia</keyword>
	<keyword>pure red cell aplasia</keyword>
	<keyword>bone marrow failure syndrome</keyword>
</DOC>